The multiplex molecular diagnostics market has anticipated a CAGR of 5.4% during the forecast period, up from US$ 23.2 Billion in 2022 to reach the valuation of US$ 39.25 Billion by 2032.
| Attributes | Details |
|---|---|
| Multiplex Molecular Diagnostic (CAGR) | 5.4% |
| Multiplex Molecular Diagnostic (2022) | US$ 23.2 Billion |
| Multiplex Molecular Diagnostic (2032) | US$ 39.25 Billion |
The demand for multiplex molecular diagnostics is anticipated to increase at a decent rate in the forecast period. An increase in economic stability leads to improve funding in healthcare and research, which leads to an increase in sales of multiplex molecular diagnostics.
An increase in the incidence of gastrointestinal, respiratory and CNS infections has led to the growth of the multiplex molecular diagnostics market. That’s why there is a huge demand for multiplex molecular diagnostics.
As the clinical symptoms of these diseases are not pathogen-specific, therefore its differential diagnosis is broad. Previously, for performing microbiologic diagnosis, one needed a combination of antigen tests, microscopy, culture, and pathogen-specific PCR assays.
Due to this, there is a widespread use of and demand for multiplex molecular diagnostics in healthcare centres.
As the multiplex molecular diagnostic approach came into practice, it simplified testing algorithms and laboratory workflow, which led to an increase in sales of multiplex molecular diagnostics.
Multiplex molecular diagnostics have significantly increased the diagnostic yield with the launch of multiplex PCRs; the tests have become more sensitive than the routine culture or antigen detection. This leads to generating sales of multiplex molecular diagnostics in the multiplex molecular diagnostics market.
Still, there are a few limitations to the current multiplex molecular diagnostics test. In its current form, multiplex molecular diagnostics cannot detect all potential pathogens, which can decline the sales of multiplex molecular diagnostics.
Besides, a negative panel result doesn’t on entirely exclude infection. Further, with panel-based methodology, current platforms offer few or limited options to select which organism targets needs to be tested. Due to this, the demand for multiplex molecular diagnostics can decrease in the marketplace.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Several industries are the key contributors to the multiplex molecular diagnostic market. Some of them are clinical research, laboratory, hospitals, academic & research centres and others.
The multiplex molecular diagnostic is used to detect infections such as tuberculosis, chlamydia, H1N1 virus and other diseases. Due to identifying such diseases, there is likely to increase in demand for multiplex molecular diagnostics by the end users.
These industries are likely to grow the multiplex molecular diagnosis market share along with sales of multiplex molecular diagnostics in the coming forecast period.
North America is anticipated to be the dominant revenue-generating region for the immunoaffinity columns multiplex molecular diagnostics market over the forecasting period. Demand for multiplex molecular diagnostics is likely to grow higher in this region as compared to others.
Many factors like well-developed high-tech diagnostic labs, the presence of a large number of key players, and favourable research funding are contributing to the high revenue generation in this region for multiplex molecular diagnostics market share.
After North America, Europe is anticipated to be the second most important region for the multiplex molecular diagnostics market share. This is attributed to the increased number of patient care and epidemiologic studies being conducted in this region.
The Asia Pacific regional multiplex molecular diagnostics market share is expected to grow at the fastest rate due to factors such as the rising adoption of advanced diagnostic technologies and the high prevalence of infectious diseases. This leads to an increase in sales of multiplex molecular diagnostics in the region.
The Middle East and Africa are expected to be the least lucrative region in the immunoaffinity columns multiplex molecular diagnostics market due to the lack of awareness about modern diagnostic techniques and the lack of advanced clinical laboratories.
Hence, there is expected to decline in the sales of multiplex molecular diagnostics in these regions.
Principal Consultant
Demand for multiplex molecular diagnostics is likely to increase in the manufacturing industries, which are playing a key role in the growth of the multiple molecular diagnostics market.
Some of the key players present in the multiplex molecular diagnostics market share include BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more. In addition, the presence of small and local manufacturers across the countries will account for competitiveness in the multiplex molecular diagnostics market.
These manufacturing companies are leading as key a player, which leads to an increase in the sales of multiplex molecular diagnostics in the forecast period.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.4% from 2022 to 2032 |
| Base year for estimation | 2022 |
| Historical data | 2015 – 2021 |
| Forecast period | 2023 – 2032 |
| Quantitative units | Revenue in USD billion and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | By Product, By Method, By End User & By Region |
| Regional scope | North America; Latin America; Europe; Middle East and; Africa (MEA); East Asia; South Asia; Oceania |
| Country scope | U.S., Canada, Mexico, Brazil, Argentina, Germany, Italy, France, U.K, Spain, Russia, India, Indonesia, Thailand, China, Japan, South Korea, Australia & New Zealand, GCC Countries, South Africa, North Africa |
| Key companies profiled | BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The growth outlook for the multiplex molecular diagnostic market is predicted up to a CAGR of 5.4% during 2022-2032.
The North America region is expected to lead the multiplex molecular diagnostic market during forecast period.
The multiplex molecular diagnostic market is likely to hold the valuation of US$ 39.25 Billion by 2032.
Healthcare Industry is expected to be a key driver in the multiplex molecular diagnostic market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Component Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Component Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Component Type, 2022-2032
5.3.1. Systems
5.3.2. Test Kits
5.3.3. Reagents and Consumables
5.4. Y-o-Y Growth Trend Analysis By Component Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Component Type, 2022-2032
Deep-dive segmentation will be available in the sample on request
6. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Indication, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Indication, 2022-2032
6.3.1. Respiratory Diseases
6.3.2. Gastrointestinal Diseases
6.3.3. CNS Infections
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
Deep-dive segmentation will be available in the sample on request
7. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2022-2032
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Specialty Clinics
7.3.4. Academic and Research Institutes
7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
Deep-dive segmentation will be available in the sample on request
8. Global Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Component Type
9.2.3. By Indication
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Component Type
9.3.3. By Indication
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Component Type
10.2.3. By Indication
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Component Type
10.3.3. By Indication
10.3.4. By End User
10.4. Key Takeaways
11. Europe Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Component Type
11.2.3. By Indication
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Component Type
11.3.3. By Indication
11.3.4. By End User
11.4. Key Takeaways
12. East Asia Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Component Type
12.2.3. By Indication
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Component Type
12.3.3. By Indication
12.3.4. By End User
12.4. Key Takeaways
13. South Asia & Pacific Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Thailand
13.2.1.3. Indonesia
13.2.1.4. Malaysia
13.2.1.5. Singapore
13.2.1.6. Australia
13.2.1.7. New Zealand
13.2.1.8. Rest of South Asia & Pacific
13.2.2. By Component Type
13.2.3. By Indication
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Component Type
13.3.3. By Indication
13.3.4. By End User
13.4. Key Takeaways
14. MEA Multiplex Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Component Type
14.2.3. By Indication
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Component Type
14.3.3. By Indication
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Multiplex Molecular Diagnostics Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Component Type
15.1.2.2. By Indication
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Component Type
15.2.2.2. By Indication
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Component Type
15.3.2.2. By Indication
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Component Type
15.4.2.2. By Indication
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Component Type
15.5.2.2. By Indication
15.5.2.3. By End User
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Component Type
15.6.2.2. By Indication
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Component Type
15.7.2.2. By Indication
15.7.2.3. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Component Type
15.8.2.2. By Indication
15.8.2.3. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Component Type
15.9.2.2. By Indication
15.9.2.3. By End User
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Component Type
15.10.2.2. By Indication
15.10.2.3. By End User
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Component Type
15.11.2.2. By Indication
15.11.2.3. By End User
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Component Type
15.12.2.2. By Indication
15.12.2.3. By End User
15.13. India
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Component Type
15.13.2.2. By Indication
15.13.2.3. By End User
15.14. Thailand
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Component Type
15.14.2.2. By Indication
15.14.2.3. By End User
15.15. Indonesia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Component Type
15.15.2.2. By Indication
15.15.2.3. By End User
15.16. Malaysia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Component Type
15.16.2.2. By Indication
15.16.2.3. By End User
15.17. Singapore
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Component Type
15.17.2.2. By Indication
15.17.2.3. By End User
15.18. Australia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Component Type
15.18.2.2. By Indication
15.18.2.3. By End User
15.19. New Zealand
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Component Type
15.19.2.2. By Indication
15.19.2.3. By End User
15.20. GCC Countries
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Component Type
15.20.2.2. By Indication
15.20.2.3. By End User
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2021
15.21.2.1. By Component Type
15.21.2.2. By Indication
15.21.2.3. By End User
15.22. Israel
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2021
15.22.2.1. By Component Type
15.22.2.2. By Indication
15.22.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Component Type
16.3.3. By Indication
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Luminex Corporation
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. GenMark Diagnostics
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. BioFire Diagnostics, LLC
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. SiemensAG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. BioMérieux
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Abbott Laboratories
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. EMPE Diagnostics AB
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. ELITechGroup
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. XCR Diagnostics
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Laboratory Corporation of America Holdings
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Multiplex Molecular Diagnostics Market
